DNLI
Denali Therapeutics Inc. NASDAQ Listed Dec 8, 2017$19.73
Mkt Cap $3.1B
52w Low $12.58
63.9% of range
52w High $23.77
50d MA $20.12
200d MA $17.52
P/E (TTM)
-6.2x
EV/EBITDA
-5.5x
P/B
3.2x
Debt/Equity
0.0x
ROE
-50.6%
P/FCF
-6.9x
RSI (14)
—
ATR (14)
—
Beta
1.10
50d MA
$20.12
200d MA
$17.52
Avg Volume
1.7M
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
161 Oyster Point Boulevard · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | -0.75 | -0.73 | +2.7% | 21.42 | -1.3% | -1.1% | -2.0% | -6.5% | -4.9% | -8.0% | — |
| Nov 6, 2025 | AMC | -0.76 | -0.74 | +2.6% | 14.41 | +1.0% | +4.2% | +8.3% | +22.0% | +21.6% | +19.0% | — |
| Aug 11, 2025 | AMC | -0.74 | -0.72 | +2.7% | 13.92 | +0.7% | -5.0% | +6.4% | +3.9% | +5.6% | +6.5% | — |
| May 6, 2025 | AMC | -0.71 | -0.78 | -9.9% | 13.97 | -0.1% | +2.5% | +3.3% | +2.9% | +5.9% | +2.1% | — |
| Feb 27, 2025 | AMC | -0.75 | -0.67 | +10.7% | 18.60 | +1.2% | -11.0% | -18.3% | -14.2% | -12.4% | -12.5% | — |
| Nov 6, 2024 | AMC | -0.60 | -0.63 | -5.0% | 29.55 | -1.0% | +0.2% | +6.1% | +6.9% | +1.2% | +0.3% | — |
| Aug 1, 2024 | AMC | -0.68 | -0.59 | +13.2% | 23.33 | -3.9% | -6.3% | -7.2% | -5.7% | -7.1% | -4.5% | — |
| May 7, 2024 | AMC | -0.67 | -0.68 | -1.5% | 16.85 | +0.9% | +12.2% | +10.8% | +8.7% | +14.5% | +17.2% | — |
| Feb 27, 2024 | AMC | -0.82 | -0.86 | -4.9% | 23.35 | -3.6% | -13.4% | -15.3% | -10.7% | -11.5% | -12.4% | — |
| Nov 7, 2023 | AMC | -0.83 | -0.72 | +13.3% | 21.23 | -5.6% | -4.9% | -19.4% | -23.6% | -23.7% | -9.9% | — |
| Aug 8, 2023 | AMC | -0.68 | 1.30 | +291.2% | 25.83 | +9.6% | -4.3% | -6.2% | -6.7% | -5.4% | -6.0% | — |
| May 8, 2023 | AMC | -0.71 | -0.80 | -12.7% | 26.56 | +0.2% | +2.9% | +6.8% | +4.3% | +5.3% | +20.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | Leerink Partners | Maintains | Outperform → Outperform | — | $20.13 | $20.28 | +0.7% | +0.6% | -3.4% | -1.3% | -0.9% | -0.3% |
| Apr 7 | Baird | Maintains | Outperform → Outperform | — | $19.38 | $19.23 | -0.8% | +0.2% | +1.2% | -0.5% | -0.8% | +0.2% |
| Mar 26 | Goldman Sachs | Maintains | Buy → Buy | — | $22.47 | $22.53 | +0.3% | -12.1% | -19.2% | -19.5% | -14.6% | -12.4% |
| Mar 26 | Baird | Maintains | Outperform → Outperform | — | $22.47 | $22.53 | +0.3% | -12.1% | -19.2% | -19.5% | -14.6% | -12.4% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.47 | $22.53 | +0.3% | -12.1% | -19.2% | -19.5% | -14.6% | -12.4% |
| Mar 26 | Stifel | Maintains | Buy → Buy | — | $22.47 | $22.53 | +0.3% | -12.1% | -19.2% | -19.5% | -14.6% | -12.4% |
| Mar 26 | Morgan Stanley | Maintains | Overweight → Overweight | — | $22.47 | $22.53 | +0.3% | -12.1% | -19.2% | -19.5% | -14.6% | -12.4% |
| Mar 25 | BTIG | Maintains | Buy → Buy | — | $20.97 | $22.62 | +7.9% | +7.2% | -5.9% | -13.4% | -13.8% | -8.4% |
| Mar 2 | BTIG | Maintains | Buy → Buy | — | $21.18 | $21.14 | -0.2% | -0.8% | -5.5% | -3.8% | -7.0% | -7.0% |
| Feb 6 | BTIG | Maintains | Buy → Buy | — | $20.02 | $20.40 | +1.9% | +5.3% | +4.1% | -1.0% | -1.6% | -4.2% |
| Dec 11 | Wedbush | Maintains | Outperform → Outperform | — | $17.57 | $17.37 | -1.1% | -1.1% | +2.3% | -1.3% | -3.1% | -4.3% |
| Dec 5 | BTIG | Maintains | Buy → Buy | — | $20.11 | $20.37 | +1.3% | -0.7% | -2.1% | -2.2% | -12.6% | -13.6% |
| Dec 5 | Wedbush | Maintains | Outperform → Outperform | — | $20.11 | $20.37 | +1.3% | -0.7% | -2.1% | -2.2% | -12.6% | -13.6% |
| Nov 4 | JP Morgan | Maintains | Overweight → Overweight | — | $15.36 | $15.10 | -1.7% | -2.9% | -3.1% | -6.2% | -2.2% | +1.6% |
| Sep 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $15.43 | $15.45 | +0.1% | +0.5% | -0.5% | -5.1% | -4.0% | -8.0% |
| Aug 18 | Morgan Stanley | Maintains | Overweight → Overweight | — | $14.70 | $14.70 | +0.0% | +0.8% | +0.7% | -1.3% | +3.6% | +5.4% |
| May 19 | BofA Securities | Maintains | Buy → Buy | — | $13.78 | $13.50 | -2.0% | +0.9% | +3.7% | -0.7% | -0.9% | -2.6% |
| May 8 | Baird | Maintains | Outperform → Outperform | — | $14.32 | $14.18 | -1.0% | +0.8% | +0.3% | +3.4% | -0.4% | -2.5% |
| May 7 | Wedbush | Maintains | Outperform → Outperform | — | $13.97 | $13.95 | -0.1% | +2.5% | +3.3% | +2.9% | +5.9% | +2.1% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.97 | $13.95 | -0.1% | +2.5% | +3.3% | +2.9% | +5.9% | +2.1% |
| Mar 10 | BofA Securities | Maintains | Buy → Buy | — | $16.69 | $16.36 | -2.0% | -10.4% | -9.9% | -4.4% | -10.8% | -9.2% |
| Mar 5 | B. Riley Securities | Maintains | Buy → Buy | — | $15.95 | $16.06 | +0.7% | +2.2% | +2.0% | +4.6% | -6.3% | -5.7% |
| Mar 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $16.56 | $16.36 | -1.2% | -8.2% | -3.7% | -1.6% | -1.8% | +0.8% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.60 | $18.83 | +1.2% | -11.0% | -18.3% | -14.2% | -12.4% | -12.5% |
| Jan 28 | Goldman Sachs | Maintains | Buy → Buy | — | $23.19 | $23.18 | -0.0% | +1.3% | +0.9% | +1.7% | +0.5% | -5.8% |
| Jan 7 | JP Morgan | Maintains | Overweight → Overweight | — | $19.82 | $18.75 | -5.4% | +6.9% | +7.2% | -3.6% | -1.2% | -5.4% |
| Jan 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.82 | $18.75 | -5.4% | +6.9% | +7.2% | -3.6% | -1.2% | -5.4% |
| Dec 16 | Stifel | Upgrade | Hold → Buy | — | $22.97 | $23.86 | +3.9% | +1.4% | +1.1% | -6.7% | -6.4% | -6.6% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.55 | $29.25 | -1.0% | +0.2% | +6.1% | +6.9% | +1.2% | +0.3% |
| Nov 1 | Jefferies | Maintains | Buy → Buy | — | $25.96 | $26.65 | +2.7% | +4.2% | +4.8% | +6.5% | +13.8% | +14.0% |
| Oct 11 | JP Morgan | Maintains | Overweight → Overweight | — | $25.74 | $25.59 | -0.6% | +8.8% | +4.2% | +4.3% | +7.5% | +6.5% |
| Sep 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $25.25 | $25.27 | +0.1% | +1.3% | +4.3% | +7.2% | +10.7% | +21.9% |
| Sep 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.12 | $25.17 | +0.2% | +0.2% | +0.5% | +0.5% | +1.9% | +4.9% |
| Sep 4 | BofA Securities | Maintains | Buy → Buy | — | $25.12 | $25.17 | +0.2% | +0.2% | +0.5% | +0.5% | +1.9% | +4.9% |
| Sep 4 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $25.12 | $25.17 | +0.2% | +0.2% | +0.5% | +0.5% | +1.9% | +4.9% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.48 | $23.13 | +2.9% | +5.3% | +2.4% | +6.5% | +5.2% | +11.2% |
| Aug 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.87 | $20.11 | -8.0% | -1.1% | +0.6% | -0.9% | +1.9% | +2.4% |
| Aug 2 | Citigroup | Maintains | Buy → Buy | — | $23.33 | $22.42 | -3.9% | -6.3% | -7.2% | -5.7% | -7.1% | -4.5% |
| Aug 2 | Wedbush | Maintains | Outperform → Outperform | — | $23.33 | $22.42 | -3.9% | -6.3% | -7.2% | -5.7% | -7.1% | -4.5% |
| Jul 10 | JP Morgan | Maintains | Overweight → Overweight | — | $20.96 | $21.31 | +1.7% | +3.3% | +10.2% | +9.1% | +11.3% | +14.2% |
| May 8 | Wedbush | Maintains | Outperform → Outperform | — | $16.85 | $17.00 | +0.9% | +12.2% | +10.8% | +8.7% | +14.5% | +17.2% |
| May 8 | Stifel | Maintains | Hold → Hold | — | $16.85 | $17.00 | +0.9% | +12.2% | +10.8% | +8.7% | +14.5% | +17.2% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.85 | $17.00 | +0.9% | +12.2% | +10.8% | +8.7% | +14.5% | +17.2% |
| Apr 9 | UBS | Maintains | Buy → Buy | — | $19.04 | $19.01 | -0.2% | +2.1% | -3.3% | +0.7% | -4.1% | -6.3% |
| Feb 29 | Goldman Sachs | Maintains | Buy → Buy | — | $20.21 | $20.80 | +2.9% | -2.1% | +3.2% | +2.2% | +1.2% | +1.5% |
| Feb 28 | Wedbush | Maintains | Outperform → Outperform | — | $23.35 | $22.51 | -3.6% | -13.4% | -15.3% | -10.7% | -11.5% | -12.4% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.35 | $22.51 | -3.6% | -13.4% | -15.3% | -10.7% | -11.5% | -12.4% |
| Feb 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.53 | $16.47 | -0.4% | +1.8% | +2.4% | +2.2% | +41.3% | +22.3% |
| Nov 8 | Wedbush | Maintains | Outperform → Outperform | — | $21.23 | $20.04 | -5.6% | -4.9% | -19.4% | -23.6% | -23.7% | -9.9% |
| Aug 31 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $23.33 | $23.31 | -0.1% | -1.0% | -0.1% | +2.2% | +5.9% | +3.6% |
No insider trades available.
8-K
Unknown — 8-K Filing
Takeda's termination of the DNL593 partnership removes a major revenue opportunity and validation for Denali, likely pressuring the stock as the company loses a well-capitalized collaborator and must reassess the drug's commercial viability independently.
Apr 3
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
Dune & Line has incorporated in Delaware and established its formal business structure (EIN 46-3872213), suggesting recent capitalization or reorganization that may affect shareholder rights and tax treatment.
Mar 31
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Denali's accelerated FDA approval of AVLAYAH, a first-in-class blood-brain barrier-penetrating biologic, validates its core technology platform and opens significant revenue potential in previously untreatable neurological diseases.
Mar 25
8-K
Denali Therapeutics Inc. -- 8-K Filing
Denali Therapeutics reported 2025 full-year results and highlighted progress in neurodegenerative disease and lysosomal storage disorder treatments, advancing its pipeline toward clinical delivery.
Feb 26
Data updated apr 25, 2026 5:30am
· Source: massive.com